7:00 a.m. – 8:00 a.m.

Palm BC

Sign-in

8:00 a.m. – 9:20 a.m.

Navigating Statistical Challenges in Early Detection Trial Design for Single-organ and Multi-Cancer Early Detection (MCED)

8:00 a.m.- 8:20 a.m.

Which sensitivity matters most in population screening studies?

• 01: Ruth Etzioni, PhD, Fred Hutchinson Cancer Center

8:20 a.m.– 8:40 a.m.

Raising the bar for launching screening trials – Which criteria should be satisfied?

• 02: Yingye Zheng, PhD, Fred Hutchinson Cancer Center

8:40 a.m. – 9:00 a.m.

What can we learn from prior cancer screening trials about stage and mortality endpoints?

• 03: Hilary Robbins PhD, International Agency for Research on Cancer (IARC) - (virtual)

9:00 a.m. – 9:20 a.m.

Q&A

9:20 a.m. – 12:10 p.m.

Collaborative Group Updates and Vision/Strategic Plan for EDRN Research

9:20 a.m. – 9:45 a.m.

9:45 a.m. – 9:55 a.m. Q&A

Breast and Gynecological Cancers

• 04: Chair: Chris Li, MD, PhD, Fred Hutchinson Cancer Center
• Co-chair: Steven Skates, PhD, Massachusetts General Hospital

9:55 a.m. – 10:25 a.m.

Break

10:25 a.m. –10:50 a.m.

10:50 a.m. –11:00 a.m. Q&A

Lung and Upper Aerodigestive Cancers and Head and Neck

• 05: Chair: Marc Lenburg, PhD, Boston University
• Co-chair: Eric Grogan, MD, Vanderbilt University Medical Center

11:00 a.m. – 11:25 a.m.

11:25 a.m. – 11:35 a.m. Q&A

Prostate and Urologic Cancers

• 06: Chair: O. John Semmes, PhD, Eastern Virginia Medical School
• Co-chair: Jeff Tosoian, MD, Vanderbilt University Medical Center

11:35 a.m. – 12:00 p.m.

12:00 p.m. – 12:10 p.m. Q&A

Gastrointestinal and Associated Cancers

• 07: Chair: Amitabh Chak, MD, UH Cleveland Medical Center,
• Co-chair: Cecilia Yeung, MD, Fred Hutchinson Cancer Center

12:10 p.m. – 1:30 p.m.

Lunch (On Your Own)

1:30 p.m. – 3:00 p.m.

Round Table Discussions Based on Methodological Approaches

Topics based on suggestions from Collaborative Groups

Imaging, Biomarkers, and Radiomics (Palm E)

• Eric Grogan, MD, Vanderbilt -Ingram Cancer Center
• Matthew Schabath, PhD, H. Lee Moffitt Cancer Center & Research Institute, Inc.
• Guillermo Marquez, PhD, National Cancer Institute

Digital Pathology – AI and ML (Joshua Tree)

• Anirban Maitra, MBBS, The University of Texas M.D. Anderson Cancer Center
• Andrew Hoofnagle, MD, PhD, University of Washington
• Sidney Fu, MD, National Cancer Institute

Spatial-Omics (Xavier)

• Cecilia Yeung, MD, Fred Hutchinson Cancer Center
• O. John Semmes, PhD, Eastern Virginia Medical School
• Indu Kohaar, PhD, National Cancer Institute

Cell Free DNA (Palm F)

• Cristian Tomasetti, PhD, City of Hope/Tgen
• Joshua LaBaer, MD, PhD, Arizona State University
• Christos Patriotis, PhD, National Cancer Institute

3:00 p.m. – 3:20 p.m.

Break

3:20 p.m. – 5:00 p.m.

Other NCI Programs

3:20 p.m. – 3:35 p.m.

3:35 p.m. – 3:40 p.m. Q&A

NCI Center for Global Health Support for Global Health Technology Research

08: Paul Pearlman, PhD, National Cancer Institute

3:40 p.m. – 3:55 p.m.

3:55 p.m. – 4:00 p.m. Q&A

Assay Validation of High Quality Markers for Clinical Studies in Cancer

09: Sumana Dey, PhD, National Cancer Institute

4:00 p.m. – 4:15 p.m.

4:15 p.m. – 4:20 p.m. Q&A

Cancer Prevention Clinical Trials Network (CP-CTNet)

10: Eva Szabo, MD, National Cancer Institute

4:20 p.m. – 4:35 p.m.

4:35 p.m. – 4:40 p.m. Q&A

Cancer Prevention-Interception Targeted Agent Discovery Program CAP-IT

11: Shizuko Sei, MD, National Cancer Institute

4:40 p.m. – 4:55 p.m.

4:55 p.m. – 5:00 p.m. Q&A

PREVENT Program Agent Development Pipeline

12: Mark Miller, PhD, National Cancer Institute

5:00 p.m. – 6:30 p.m.

Development of Trans-EDRN BRL Projects

6:30 p.m.

Adjourn for the Day